Shares of West Pharmaceutical Servs WST remained unaffected after the company reported Q2 results.
Quarterly Results
Earnings per share rose 96.80% over the past year to $2.46, which beat the estimate of $1.74.
Revenue of $723,600,000 rose by 37.25% from the same period last year, which beat the estimate of $669,380,000.
Outlook
The upcoming fiscal year's EPS expected to be between $8.05 and $8.20.
The upcoming fiscal year's revenue expected to be between $2,760,000,000 and $2,785,000,000.
How To Listen To The Conference Call
Date: Jul 29, 2021
Time: 09:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/f966zihe
Technicals
52-week high: $385.30
52-week low: $253.85
Price action over last quarter: Up 16.89%
Company Overview
West Pharmaceutical Services is a Pennsylvania-based medical supplies company that operates as a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West develops, manufactures, and distributes elastomer-based supplies for the containment and administration of injectable drugs, including basic equipment such as syringes, stoppers, and plungers, along with somewhat more complicated devices including auto-injectors and other self-injection platforms. The company reports in two segments: proprietary products (77% of 2020 sales) and contract-manufactured products (23%). It generates 55% of its revenue from international markets and 45% from the United States.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.